IDH2 and astrocytoma (excluding glioblastoma): However, recently Pekmezci et al. studied TERTp and ATRX mutation status and their prognostic value in large cohorts from the UCSF and Mayo clinics and The Cancer Genome Atlas (TCGA), and found that the wildtype (WT) TERTp group was associated with good prognosis only in IDH1/IDH2 WT (IDH-WT) astrocytomas (grade II and III), while in other groups such as IDH-mutant astrocytomas (grades II and III) and GBMs (grade IV) with or without IDH-mutation, TERTp mutation status was not a statistically significant prognostic factor [23].